InvestorsHub Logo
Followers 185
Posts 2462
Boards Moderated 0
Alias Born 02/10/2017

Re: None

Thursday, 01/14/2021 10:22:16 AM

Thursday, January 14, 2021 10:22:16 AM

Post# of 239
Float is way too small to handle the masses. Just the beginning.


my top pick for 2021



Cathie Wood discusses Genome gene editing stocks will become the next FANG stocks.





this stock can literally double or triple in a blink of an eye with its tiny float of 35 million half of the shares are owned by insiders and institutions like ARKG cathie woods genome ETF


if you have done your research this multiple hammers and catalyst this company is about to drop.


always early..



EVGN gene editing AI computational platform that Cathie Wood from ARKG is personally backing I have seen multiple gene editing stocks move 1000% in a matter of months that Cathie is invested in EVGN is next.



https://www.evogene.com/


EVGN Subsidiaries:

Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.

1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf


Evogene to Participate in CRISPR-IL Consortium to Provide End-to-End Artificial Intelligence System for Genome-Editing

Evogene's work in the consortium is expected to include the broadening of its artificial intelligence capabilities that are expected to extend the range of its GENErator AI solution (part of Evogene's CPB platform). Evogene's GENErator AI solution already includes computational capabilities directing "which" edit should be made to achieve a specific trait; and the capabilities developed within the framework of the consortium aim to improve "how" these edits are made.
https://www.prnewswire.com/il/news-releases/evogene-to-participate-in-crispr-il-consortium-to-provide-end-to-end-artificial-intelligence-system-for-genome-editing-301069960.html



Genome Stocks-Gene Editing.
$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$CRSP 13 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 200 million market cap 35 million shares 45% owned by institutions & insiders




$EVGN

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent EVGN News